Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia.
about
Seasonal H3N2 influenza A virus fails to enhance Staphylococcus aureus co-infection in a non-human primate respiratory tract infection modelPredictive Factors of Methicillin-Resistant Staphylococcus aureus Infection in Elderly Patients with Community-Onset Pneumonia.Year in review 2012: Critical Care--respiratory infectionsComparison of methicillin-resistant Staphylococcus aureus community-acquired and healthcare-associated pneumoniaAdherence to therapeutic guidelines for patients with community-acquired pneumonia in Australian hospitalsStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia.Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsComparison of clinical prediction models for resistant bacteria in community-onset pneumonia.Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatmentRole of Interleukin-12 in Protection against Pulmonary Infection with Methicillin-Resistant Staphylococcus aureus.Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management.Combination Therapy of LysGH15 and Apigenin as a New Strategy for Treating Pneumonia Caused by Staphylococcus aureus.Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations.The Spl Serine Proteases Modulate Staphylococcus aureus Protein Production and Virulence in a Rabbit Model of Pneumonia.Molecular characterization of Staphylococcus aureus and influenza virus coinfections in patients with fatal Pneumonia.Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia.Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.The changing microbiologic epidemiology of community-acquired pneumonia.Methicillin-resistant Staphylococcus aureus as a cause of invasive infections in Central Africa: a case report and review of the literature.The hospitalist perspective on treatment of community-acquired bacterial pneumonia.Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update.Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.Versatile molybdenum disulfide based antibacterial composites for in vitro enhanced sterilization and in vivo focal infection therapy.Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes.HMGB1 as a drug target in staphylococcal pneumonia.Microarray-based identification of human antibodies against Staphylococcus aureus antigens.Community-acquired pneumonia: why aren't national antibiotic guidelines followed?Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Testing Reduces the Duration of MRSA-Targeted Therapy in Patients with Suspected MRSA PneumoniaIn vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship.Editorial Commentary: The Mismatch Between Physicians' Expectations and Microbiologic Reality.Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum.La pneumonie non compliquée chez les enfants et les adolescents canadiens en santé : points de pratique sur la prise en charge.Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
P2860
Q30571941-1437EC58-E7D3-4B8B-A4C5-A553F544E35DQ33567395-858707B5-F05D-450D-8319-5BE1F3AAFE9EQ33753788-6AB50F6B-FD12-442B-AAD0-1DC421755F28Q33822603-4A1FD36C-8F31-4F32-89FC-009D8F70781AQ34203870-D337588B-98BA-4783-9DD6-4A493E91C831Q34478074-55E9F9D7-E875-4EFB-88FA-79849A02BC61Q34928386-B3C699D4-F319-4635-816C-7522E38D69A9Q34999500-EB138778-2D85-4EF3-8E6B-AC165E619AC9Q35732814-31FDB0EB-ED9F-4A1A-B24D-C1609659A6F5Q35780916-A6B6A8A8-0358-4C84-9AD2-A7B7A243D764Q36075866-9467A314-57EA-4389-BFF5-75D00AA69147Q36141276-29B457FB-B6AB-4B3B-A149-94E99A22F111Q36425466-639E6AB7-2EA9-4251-8415-CC5290B8B75EQ36434131-F16DEDAD-1B62-4F81-A5EE-C57566E27115Q36595082-34ADBC92-AF8C-4647-BCC9-F897E5E6D9C7Q37335319-3FD43D8B-7FD2-40AA-AFD9-B2267606CC68Q37336172-7AFC0C7F-CA77-4A86-BB19-08D3BAF4B4C9Q37544795-79807A0E-F885-4FE7-A9F7-4E39491CDB42Q38038043-004872F8-BB36-484F-ACF0-B98C2E9F0D09Q38106836-EAC57CF7-8BF0-4128-90E1-4ED5EC161C95Q38117077-E00F17CD-16B6-4A09-B5E1-7D487B50DE32Q38160635-BF847CE6-12F3-4356-BE7B-88660B2D5153Q38182023-B5822F78-88D7-40DD-9EF7-69111CD67D64Q38200827-19FA129C-A0CF-4D61-B41A-6B5D4AEEDD80Q38853784-718FD71B-54AB-4A84-B6E5-967F3B90D7DDQ39157514-5E28FF94-2D33-4DB7-8C3C-ED9659285EC0Q40663025-E650FE72-54D4-474D-9C85-09565538F96EQ40681222-95E9ECC4-927A-4876-803D-8649D39906D9Q40688827-2E77EF3D-BB1A-41C5-846E-767C784684A8Q41486894-CC0C1B0C-257D-4F76-A5F6-C3D355134B5DQ41640948-C687CF0B-53A5-469C-8295-2BD7685C684AQ41695428-8F6A9A26-C030-4B20-BA5B-43C0E673D696Q41713696-5773C69C-2025-4297-ACC9-66E5E43BA768Q41871463-CC48B856-3B2B-4726-9C5B-A6E1E068F63FQ42573674-2EC0FCC9-3E36-4AA3-A210-69528E3DE410Q43449557-23C70B77-43A7-4957-AFBF-98BCAE85B619Q43974180-53DEB1B3-469D-4DA6-ABE1-89E1BF48A48BQ46486735-C6D8403D-8BD5-4ACE-BA27-48FE565D7B3BQ46887329-E90CB4FF-D2E2-4E6B-A692-45AE77C1089CQ54292686-3732337C-B3D0-464D-917E-492977805A6C
P2860
Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@en
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@nl
type
label
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@en
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@nl
prefLabel
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@en
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@nl
P2093
P356
P1476
Prevalence of methicillin-resi ...... community-acquired pneumonia.
@en
P2093
Anusha Krishnadasan
David A Talan
EMERGEncy ID NET Study Group
Greg E Fosheim
Gregory J Moran
Rachel J Gorwitz
Valerie Albrecht
P304
P356
10.1093/CID/CIS022
P407
P577
2012-04-01T00:00:00Z